Abraxis BioScience, Inc. (Acquired by Celgene Corporation)
Press releases archived for reference only.
11755 Wilshire Boulevard, 20th Floor
Los Angeles
California
90025
United States
171 articles about Abraxis BioScience, Inc. (Acquired by Celgene Corporation)
-
Ex-Abraxis BioScience, Inc. Cancer Researcher-Turned-Billionaire Starts New Company
1/29/2013
-
Celgene (Summit, New Jersey) Completes Acquisition of Abraxis BioScience, Inc.
10/15/2010
-
Celgene Corporation and Abraxis BioScience, Inc. Announce Shareholder Vote in Favor of Merger
10/14/2010
-
Antitope Announces EpiScreen Collaboration with Abraxis BioScience, Inc.
9/28/2010
-
Celgene Corporation/Abraxis BioScience, Inc. Receive Verbal Confirmation of Early Termination of Hart-Scott-Rodino (HSR) 30-Day Waiting Period
8/4/2010
-
Abraxis BioScience, Inc. and Specialised Therapeutics Australia Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand
7/29/2010
-
Abraxis BioScience, Inc.'s ABRAXANE(R) Approved for Marketing in Japan for Breast Cancer
7/23/2010
-
Celgene to Buy Abraxis BioScience, Inc. for $2.9 Billion
6/30/2010
-
Abraxis BioScience, Inc. Release: Among the Toughest Cancers to Treat, New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma
6/8/2010
-
Abraxis BioScience, Inc. Release: American Society of Clinical Oncology Presentations Offer New Insights into Role of nab(R)-Chemotherapy Based Breast Cancer Chemotherapy Treatment
6/8/2010
-
Abraxis BioScience, Inc. Release: Results of Phase 3 ABRAXANE(R) Combination Trial In First-Line Non-Small Cell Lung Cancer Show 31 Percent Improvement In Response Rate Compared With Taxol Combination
6/7/2010
-
Abraxis BioScience, Inc. Release:New Data Demonstrates Potential of ABRAXANE in Difficult-to-Treat Refractory Invasive Bladder Cancer
6/2/2010
-
Abraxis BioScience, Inc.'s Second Trial with ABRAXANE to Demonstrate Increased Survival in Patients with Advanced Pancreatic Cancer
5/21/2010
-
Abraxis BioScience, Inc.: Over 30 Scientific Presentations at Abraxis BioScience, Inc. Exploring ABRAXANE's Expanded Potential in Multiple Difficult-to-Treat Cancers
5/18/2010
-
Abraxis BioScience, Inc. Reports First Quarter 2010 Financial Results
5/6/2010
-
Abraxis BioScience, Inc.'s ABRAXANE(R) in Combination with Bevacizumab Shows Promise in New Model of Triple Negative Breast Cancer
4/20/2010
-
Abraxis BioScience, Inc.'s ABRAXANE(R) In Combination With Gemcitabine Increases Survival In First-Line Treatment Of Advanced Pancreatic Cancer In Phase I/II Study
4/19/2010
-
Abraxis BioScience, Inc. Hires Advisers to Weigh Sale of Company
4/14/2010
-
Scottish Medicines Consortium Accepts Abraxis BioScience, Inc.'s ABRAXANE(R) for Use within National Health Service for Scotland
4/13/2010
-
Abraxis BioScience, Inc. Founder & Executive Chairman to Present at 7th Annual World Health Care Congress
4/13/2010